Tellurian shares initially spiked 30% on the report, but the stock has given back some of the gains. According to data from Benzinga Pro, 20.79% of Tellurian shares are being sold short which can ...

HOUSTON--(BUSINESS WIRE)-- As previously announced, on October 8, 2024, Tellurian Inc. (“Tellurian”) completed its merger pursuant to the Agreement and Plan of Merger (the “Merger Agreement ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Currently, the company's market capitalization stands at approximately $892.985 million, with a recent stock price of $0.999, reflecting a year-to-date increase of 33.75%. Tellurian's financial ...

As part of the merger agreement, each outstanding share of Tellurian’s common stock and Series C Convertible Preferred Stock was converted into a cash consideration. Additionally, Tellurian ...

Woodside has acquired all issued and outstanding Tellurian common stock for approximately $900 million cash, or $1.00 per share. The implied enterprise value is approximately $1,200 million.1 Woodside ...

Tokyo Gas in talks with Woodside Energy for a stake in Louisiana LNG project, part of strategy to secure U.S. gas supply.

In other developments, Tellurian has corrected an omission in its certificate of incorporation to include details of its Series C Convertible Preferred Stock. This administrative adjustment does not ...

Furthermore, Tellurian has amended its certificate of incorporation to include details of its Series C Convertible Preferred Stock and agreed to sell its Haynesville gas-producing assets to Aethon ...

Shares of Tellurian Inc. (NASDAQ: TELL) shares rose sharply in pre-market trading following a report suggesting the company hired Lazard to explore a possible sale. Tellurian shares jumped 16.3% ...

Tellurian shares jumped 16.3% to $0.6050 in ... TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode Therapeutics shares dipped 24.3% to $0.8248 ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...